8 results
The objective of the trial is to confirm efficacy and a favorable benefit-risk ratio for BIBF 1120 in the treatment of IPF at the dose of 150 mg bid compared to placebo.
This study aims to investigate the sensitivity and specificity of the history and physical examination for the diagnosis of giant cell arteritis, compared with the superficial temporal artery biopsy, and get more insight into the positive and…
to offer continuation of BIBF 1020 treatment for patients with IPF who have completed a prior clinical trial with that drug.establish the long term tolerability and safety profile of BIBF 1120 in IPF.
1) To investigate if it is possibility to measure neural activation (CBF) in the DA brain stem nuclei and the functionally associated brain regions with ASL. 2) To investigate the effect of increased DA on activation in the DA system during resting…
See page 9Primary Objective:The primary objective of this study is to explore the relationship between MPH and academic activity and the mediating roles of ADHD behaviours, cognitive deficits and motivational deficits in this relationship. Therefore…
The aim of this extension trial is to provide BIBF 1120 treatment for all patients who have completed the 52 weeks treatment period and the follow up period in the phase III placebo controlled parent trial 1199.34, who may have experienced benefit…
The overall objective of this study is to evaluate the efficacy and safety of neoGAA in treatment-naïve patients with LOPD as compared to alglucosidase alfa, when this is administered biweekly for a period of 49 weeks. Also, there is an open-label…
The primary objective of this study is to investigate if shear-wave elastography and contrast-enhanced ultrasonography can identify those patients most suitable fir an intervention (surgery or endoscopic balloon dilation) and those patients that…